These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

346 related items for PubMed ID: 33413096

  • 1. Effect of PCSK9 inhibitor on lipoprotein particles in patients with acute coronary syndromes.
    Li T, Zhang Y, Cong H.
    BMC Cardiovasc Disord; 2021 Jan 07; 21(1):19. PubMed ID: 33413096
    [Abstract] [Full Text] [Related]

  • 2. Effects of evolocumab in individuals with type 2 diabetes with and without atherogenic dyslipidemia: An analysis from BANTING and BERSON.
    Lorenzatti AJ, Monsalvo ML, López JAG, Wang H, Rosenson RS.
    Cardiovasc Diabetol; 2021 Apr 30; 20(1):94. PubMed ID: 33941192
    [Abstract] [Full Text] [Related]

  • 3. Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial.
    Schwartz GG, Steg PG, Szarek M, Bittner VA, Diaz R, Goodman SG, Kim YU, Jukema JW, Pordy R, Roe MT, White HD, Bhatt DL, ODYSSEY OUTCOMES Committees and Investigators*.
    Circulation; 2020 May 19; 141(20):1608-1617. PubMed ID: 32223446
    [Abstract] [Full Text] [Related]

  • 4. Treatment with PCSK9 inhibitors induces a more anti-atherogenic HDL lipid profile in patients at high cardiovascular risk.
    Ingueneau C, Hollstein T, Grenkowitz T, Ruidavets JB, Kassner U, Duparc T, Combes G, Perret B, Genoux A, Schumann F, Bobbert T, Steinhagen-Thiessen E, Martinez LO.
    Vascul Pharmacol; 2020 Dec 19; 135():106804. PubMed ID: 32987194
    [Abstract] [Full Text] [Related]

  • 5. Lipid management in ACS: Should we go lower faster?
    Gencer B, Mach F.
    Atherosclerosis; 2018 Aug 19; 275():368-375. PubMed ID: 30015301
    [Abstract] [Full Text] [Related]

  • 6. Treatment with PCSK9 inhibitors reduces atherogenic VLDL remnants in a real-world study.
    Hollstein T, Vogt A, Grenkowitz T, Stojakovic T, März W, Laufs U, Bölükbasi B, Steinhagen-Thiessen E, Scharnagl H, Kassner U.
    Vascul Pharmacol; 2019 May 19; 116():8-15. PubMed ID: 30910670
    [Abstract] [Full Text] [Related]

  • 7. Residual Inflammatory Risk on Treatment With PCSK9 Inhibition and Statin Therapy.
    Pradhan AD, Aday AW, Rose LM, Ridker PM.
    Circulation; 2018 Jul 10; 138(2):141-149. PubMed ID: 29716940
    [Abstract] [Full Text] [Related]

  • 8. Systematic Review and Network Meta-Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia.
    Toth PP, Worthy G, Gandra SR, Sattar N, Bray S, Cheng LI, Bridges I, Worth GM, Dent R, Forbes CA, Deshpande S, Ross J, Kleijnen J, Stroes ESG.
    J Am Heart Assoc; 2017 Oct 02; 6(10):. PubMed ID: 28971955
    [Abstract] [Full Text] [Related]

  • 9. Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies.
    Ray KK, Del Prato S, Müller-Wieland D, Cariou B, Colhoun HM, Tinahones FJ, Domenger C, Letierce A, Mandel J, Samuel R, Bujas-Bobanovic M, Leiter LA.
    Cardiovasc Diabetol; 2019 Nov 09; 18(1):149. PubMed ID: 31706300
    [Abstract] [Full Text] [Related]

  • 10. Metformin-Induced Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition Further Decreases Low-Density Lipoprotein Cholesterol Following Statin Treatment in Patients With Coronary Artery Disease and Without Diabetes.
    Hu D, Qin D, Kuang J, Yang Y, Weng S, Chen J, Wu S, Wang S, Mao L, Peng D, Yu B.
    J Cardiovasc Pharmacol; 2024 Aug 01; 84(2):261-269. PubMed ID: 38922587
    [Abstract] [Full Text] [Related]

  • 11. Effects of Evolocumab on the Postprandial Kinetics of Apo (Apolipoprotein) B100- and B48-Containing Lipoproteins in Subjects With Type 2 Diabetes.
    Taskinen MR, Björnson E, Kahri J, Söderlund S, Matikainen N, Porthan K, Ainola M, Hakkarainen A, Lundbom N, Fermanelli V, Fuchs J, Thorsell A, Kronenberg F, Andersson L, Adiels M, Packard CJ, Borén J.
    Arterioscler Thromb Vasc Biol; 2021 Feb 01; 41(2):962-975. PubMed ID: 33356392
    [Abstract] [Full Text] [Related]

  • 12. Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes.
    Roe MT, Li QH, Bhatt DL, Bittner VA, Diaz R, Goodman SG, Harrington RA, Jukema JW, Lopez-Jaramillo P, Lopes RD, Louie MJ, Moriarty PM, Szarek M, Vogel R, White HD, Zeiher AM, Baccara-Dinet MT, Steg PG, Schwartz GG.
    Circulation; 2019 Nov 05; 140(19):1578-1589. PubMed ID: 31475572
    [Abstract] [Full Text] [Related]

  • 13. Lipoprotein Apheresis and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia: A One Center Study.
    Kolovou V, Katsiki N, Makrygiannis S, Mavrogieni S, Karampetsou N, Manolis A, Melidonis A, Mikhailidis DP, Kolovou GD.
    J Cardiovasc Pharmacol Ther; 2021 Jan 05; 26(1):51-58. PubMed ID: 32729335
    [Abstract] [Full Text] [Related]

  • 14. Effect of PCSK9 Inhibition by Alirocumab on Lipoprotein Particle Concentrations Determined by Nuclear Magnetic Resonance Spectroscopy.
    Koren MJ, Kereiakes D, Pourfarzib R, Winegar D, Banerjee P, Hamon S, Hanotin C, McKenney JM.
    J Am Heart Assoc; 2015 Nov 19; 4(11):. PubMed ID: 26586732
    [Abstract] [Full Text] [Related]

  • 15. The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism.
    Marston NA, Gurmu Y, Melloni GEM, Bonaca M, Gencer B, Sever PS, Pedersen TR, Keech AC, Roselli C, Lubitz SA, Ellinor PT, O'Donoghue ML, Giugliano RP, Ruff CT, Sabatine MS.
    Circulation; 2020 May 19; 141(20):1600-1607. PubMed ID: 32223429
    [Abstract] [Full Text] [Related]

  • 16. From lipoprotein apheresis to proprotein convertase subtilisin/kexin type 9 inhibitors: Impact on low-density lipoprotein cholesterol and C-reactive protein levels in cardiovascular disease patients.
    Zenti MG, Altomari A, Lupo MG, Botta M, Bonora E, Corsini A, Ruscica M, Ferri N.
    Eur J Prev Cardiol; 2018 Nov 19; 25(17):1843-1851. PubMed ID: 30058841
    [Abstract] [Full Text] [Related]

  • 17. Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute coronary syndrome: a systematic review and meta-analysis.
    Hosseini K, Soleimani H, Maleki S, Nasrollahizadeh A, Tayebi S, Nelson J, Heffron SP.
    BMC Cardiovasc Disord; 2024 Jul 30; 24(1):395. PubMed ID: 39080549
    [Abstract] [Full Text] [Related]

  • 18. Effect of evolocumab therapy on coronary fibrous cap thickness assessed by optical coherence tomography in patients with acute coronary syndrome.
    Yano H, Horinaka S, Ishimitsu T.
    J Cardiol; 2020 Mar 30; 75(3):289-295. PubMed ID: 31495548
    [Abstract] [Full Text] [Related]

  • 19. Efficacy evaluation of PCSK9 monoclonal antibody (Evolocumab) in combination with Rosuvastatin and Ezetimibe on cholesterol levels in patients with coronary heart disease (CHD): A retrospective analysis from a single center in China.
    Liu Y, Han B.
    Transpl Immunol; 2022 Apr 30; 71():101444. PubMed ID: 34375677
    [Abstract] [Full Text] [Related]

  • 20. Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab versus control.
    Vallejo-Vaz AJ, Ray KK, Ginsberg HN, Davidson MH, Eckel RH, Lee LV, Bessac L, Pordy R, Letierce A, Cannon CP.
    Atherosclerosis; 2019 Sep 30; 288():85-93. PubMed ID: 31349086
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.